ABEO — ABEONA THERAPEUTICS INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 318306 ·
Last close
$5.29
Market Cap
$302.50M
52W High
$7.65
52W Low
$4.00
ADV30
1,311,112
Next earnings
2026-11-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 11,380,000 | 7,203,000 | -13,653,000 | -20,191,000 | 179,507,000 | 56,229,000 | 51,449,000 |
| Mar 2026 | 8,720,000 | 6,024,000 | -23,033,000 | -17,075,000 | 198,494,000 | 61,374,000 | 53,555,000 |
| Dec 2025 | 5,420,000 | 2,583,000 | -22,911,000 | -20,460,000 | 219,570,000 | 78,437,000 | 60,354,000 |
| Sep 2025 | 0 | -488,000 | -24,018,000 | -5,161,000 | 231,095,000 | 82,884,000 | 59,862,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-77,728,000
Investing CF
$105,778,000
Financing CF
$17,050,000
CapEx
$-7,509,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$1.07
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-759,150,000
Inventory
$6,054,000
Receivables
$6,709,000
ST Investments
$106,897,000
EBIT TTM
$69,811,000
Pretax Income TTM
$66,239,000
Interest Exp TTM
$3,572,000
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$25,520,000
EBITDA
$-80,789,000
Free Cash Flow
$-73,398,752
Enterprise Value
$182,697,456
Total Cash
$146,826,000
Total Debt
$19,872,000
Shares Out
57,184,017
Trailing EPS
$-1.21
Book Value
$2.24
ROE
-43.1%
ROA
-24.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 5,820,000 | -89,448,000 | 71,183,000 | 219,570,000 | 60,354,000 | 159,216,000 | -76,326,000 |
| Dec 2024 | 0 | -64,211,000 | -63,734,000 | 108,931,000 | 64,900,000 | 44,031,000 | -56,015,000 |
| Dec 2023 | 3,500,000 | -48,200,000 | -54,188,000 | 64,002,000 | 49,176,000 | 14,826,000 | -37,009,000 |
| Dec 2022 | 1,414,000 | -45,257,000 | -39,696,000 | 64,214,000 | 37,453,000 | 26,761,000 | -43,483,000 |
TTM Snapshot
Revenues TTM
$2,309,000
NetIncome TTM
$-15,533,000
OpCashFlow TTM
$0
Assets (Latest)
$16,582,000
Forward EPS
$-0.19
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $5.00 · spot: $5.29 · call volume: 995 · put volume: 227
Expected Move to 2026-12-18:
±$1.50
(28.36%) —
implied range
$3.79 –
$6.79
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| EVMN | Evommune, Inc. | $304.49M | $8.39 | — |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | $305.46M | $3.81 | — |
| VNDA | Vanda Pharmaceuticals Inc. | $312.59M | $5.17 | — |
| CYDY | CytoDyn Inc. | $290.76M | $0.21 | — |
| UPB | Upstream Bio, Inc. | $290.29M | $5.30 | — |
News headlines (Yahoo Finance, 1h cache)
Abeona Therapeutics Highlights ZEVASKYN Launch Momentum, Revenue Growth at H.C. Wainwright
2026-09-22 22:02 · Yahoo
Abeona Expands ZEVASKYN Network as RDEB Launch Gains Momentum
2026-09-22 08:02 · Yahoo
Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)
2026-09-18 11:30 · Yahoo
ABEO Stock Gains On Approval For A Drug Abeona Sold, Rating For The One It Sells
2026-09-17 23:33 · Yahoo
Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®
2026-09-16 11:30 · Yahoo
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
2026-09-02 11:30 · Yahoo
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-01 11:30 · Yahoo
Abeona Therapeutics Inc (ABEO) (Q2 2026) Earnings Call Highlights: ZEVASKYN Revenue Surges 31% ...
2026-08-17 19:03 · Yahoo
ABEO: Zevaskyn® Launch Gains Momentum
2026-08-17 15:05 · Yahoo
Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update
2026-08-13 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.